Technical Data
A0005-05
Abl SH3 Domain
|
Technical Data |
|
A0005-05 |
Abl SH3 Domain |
|
|
Description: The v-abl oncogene, which was originally described in the murine Abelson retrovirus, encodes a non-receptor tyrosine kinase that can mediate cell transformation (1–3). Mammalian c-Abl is associated with normal cell growth and differentiation, and is distributed in the nucleus, and the cytoplasm in association with F-actin. In the nucleus, c-Abl has been shown to bind chromatin in a cell cycle regulated manner. Deletion of the F-actin binding and the chromatin binding regions of c-Abl has been shown to block cell growth despite the production of an active tyrosine kinase. In chronic myelogenous leukemia (CML), the c-abl protooncogene translocates from chromosome 9 to the breakpoint cluster region (bcr) on chromosome 22 forming the Philadelphia chromosome (4). This translocation causes the expression of a novel 210kD Abl-Bcr fusion gene product which is only found in malignant cells and is believed to play a crucial role in the pathogenesis of CML. Applications: Western Immunoblot Analysis: This lot was tested by using the antibody (1ug/ml) to detect Abl-Bcr (~ 210kDa) and c-Abl (~ 140kDa) in human K562 leukemia cells and NFC murine erythroleukemia cells. Note: The amount of c-Abl tends to be low in many cell lines and c-Abl was not detected using RIPA lysates from human Jurkat, Raj and Hut lymphoid cell lines, or murine Wehi myeloid cell line. Immunoprecipitation: 15ug immunoprecipitates Abl-Bcr (~210kDa) and c-Abl (~ 140kDa) from a lysate of human K562 leukemia cells. Storage and Stability: May be stored at 4°C for short-term only. For long-term storage and to avoid repeated freezing and thawing, add glycerol (25–50%) and freeze at -20°C. Aliquots are stable for at least 12 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer. |
|
|||||||||||
|
||||||||||||
|
||||||||||||
|
||||||||||||